Amgen Inc.

University of California

University of Georgia Research Foundation, Inc.

Beverly S Adler

Kenneth William Walker

Shaw-Fen Sylvia Hu

Francis Hall Martin

Leslie Phillip Miranda

John Kevin Sullivan

Hung Q Nguyen

Colin Victor Gegg, Jr

Joseph G McGivern

Jeffrey K Browne

Eryn Ujita-Lee

Taruna Arora Khare

Karen J Colley

James C Paulson

Jasminder Weinstein

Nevis L Fregien

Mohamed G Shoreibah

James Michael Pierce

J Michael Pierce

James G Paulson

Disclosed is a composition of matter comprising a ShK toxin peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

DNA encoding chimeric toxin peptide fusion proteins and vectors and mammalian cells for recombinant expression

Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

Methods of using conjugated toxin peptide therapeutic agents

Conjugated toxin peptide therapeutic agents

The present invention provides substantially purified UDP-N-acetylglucosamine: .alpha.-6-D-mannoside .beta.-1,6-N-acetylglucosaminyl transferase (GlcNAc T-V; EC 2.4.1.155) proteins and antibodies which specifically bind GlcNAc T-V. The present invention also provides polynucleotide sequences and oligonucleotide probes capable of specifically hybridizing to nucleic acid sequences which encode GlcNAc T-V, and cDNA and genomic clones encoding GlcNAc T-V, as well as nucleotide sequences encoding GlcNAc T-V, as specifically exemplified by GlcNAc T-V coding sequences from rat, hamster, mouse and human.

N-acetylglucosaminyltransferase V proteins and coding sequences

A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a retention signal. The resulting altered enzyme becomes soluble and secretable by the cell without losing its catalytic activity. Secretion of the soluble glycosyltransferase by the cell provides for increased production and simplified recovery of glycosyltransferase.

Method for producing secretable glycosyltransferases and other golgi

The present invention provides a substantially purified UDP-N-acetylglucosamine:.alpha.-6-D-mannoside .beta.-1,6-N-acetylglucosaminyltransferase (GlcNAc T-V; EC 2.4.1.155) and antibodies which specifically bind GlcNAc T-V. The present invention also provides polynucleotide sequences and oligonucleotide probes capable of specifically hybridizing to nucleic acid sequences which encode GlcNAc T-V, and cDNA and genomic clones encoding GlcNAc T-V, as well as nucleotide sequences encoding GlcNAc T-V, as specifically exemplified by a GlcNAc T-V coding sequence from rat.

N-acetylglucosaminyltransferase V gene

A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a r

Method for producing secretable glycosyltransferases and other Golgi

Growing community of inventors

Newbury Park, CA, United States of America

Beverly S Adler